Media

Board Change

 

25 June 2019

Jesper Ovesen has advised the Board of ConvaTec Group Plc ("ConvaTec" or "the Company") that he wishes to retire as a Non-Executive Director of the Company on 28th June 2019.

Margaret Ewing, Senior Independent Director, will succeed Jesper as Chair of the Audit and Risk Committee and Regina Benjamin will also become a member of the Committee. Regina will also be appointed as a member of the Remuneration Committee. These appointments will take effect from 28th June.

Margaret joined the Board of ConvaTec in August 2017. She has strong executive and non-executive experience with large listed businesses and is currently a Non-Executive Director and Chair of the Audit and Risk Committee of ITV plc and a Non-Executive Director and member of the Audit and Compliance Committee of International Airlines Group plc. She was previously CFO of BAA plc and Trinity Mirror plc and Executive Board member of Deloitte LLP.

Rick Anderson, Executive Chairman, commented "On behalf of the Board I would like to thank Jesper for his valuable contribution to ConvaTec since he became a Director in 2016.

We are very pleased that Margaret has agreed to become the Chair of the Audit and Risk Committee, where her knowledge and experience will be most valuable to ConvaTec."

This announcement is made in accordance with Listing Rule 9.6.11R(1).

 

 

Enquiries

 
Analysts and Investors 
                                                                                                                     

investorrelations@convatec.com

 

 

 

John Crosse, VP Investor Relations

+44 (0)7500 141435

 

 

 

Mark Reynolds, Director Investor Relations

+44 (0)7551 036625

 

 

 



Media


mediarelations@convatec.com

 

 

 

Bobby Leach, VP Group Corporate Affairs                      

+44 (0)7770 842226

 

 

 

James Bradley / Alastair Elwen, Finsbury

+44 (0)207 2513801

 

 

 

  

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.

 

 

Cookies are needed for this website to work optimally. They also help us to know a little bit about how you use our website, which improves the browsing experience.  Cookies on this site are used for traffic measurement and optimisation of page content only. By continuing to browse on this website, you indicate your consent to the use of cookies.  You may block the use of cookies by following the "How to block and avoid cookies" instructions

Learn more about our Cookie policy